Oncology Institute Projects Strong 2025 Revenue Growth

Meet Your ETF AI Analyst

• Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
• Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Oncology Institute ( (TOI) ) just unveiled an update.

The Oncology Institute has released an investor presentation highlighting its strategic plans and financial outlook. The company anticipates over 20% revenue growth in 2025 and aims to achieve EBITDA positive by the fourth quarter of 2025. The presentation outlines multiple growth channels, including strategic M&A, expanding contracts, and increasing specialty pharmacy services, which are expected to enhance the company’s market positioning and operational efficiency.

The most recent analyst rating on (TOI) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.

Spark’s Take on TOI Stock

According to Spark, TipRanks’ AI Analyst, TOI is a Neutral.

The overall stock score of 45 reflects significant financial challenges, including high leverage and negative equity, which weigh heavily on the score. Despite positive earnings call highlights such as revenue growth and strategic advancements, technical indicators and valuation metrics remain weak, contributing to a cautious outlook.

To see Spark’s full report on TOI stock, click here.

More about Oncology Institute

The Oncology Institute, Inc. operates in the healthcare industry, focusing on oncology services. It provides a value-based care platform for cancer treatment, offering services such as medical oncology, radiation oncology, specialty pharmacy, and clinical research. The company aims to deliver patient-first, physician-led care with deep payor collaboration, emphasizing cost control and improved patient outcomes.

Average Trading Volume: 1,886,372

Technical Sentiment Signal: Buy

Current Market Cap: $320.7M